newsfilter
← Latest News
Business Wire·

Better Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Updates

U.S. FDA accepted the company's submission of its de novo request for BT-001 investigational prescription digital therapy for type 2 diabetes in adults BT-001 pivotal clinical trial 90-day results published in